Related references
Note: Only part of the references are listed.Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
Robert Mason et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
Restoration and Enhancement of Immunogenic Cell Death of Cisplatin by Coadministration with Digoxin and Conjugation to HPMA Copolymer
Yucheng Xiang et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models
Bin Du et al.
CANCER LETTERS (2020)
AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells
Maria L. Lotsberg et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis
Tat San Lau et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
Jesus Vera Aguilera et al.
MELANOMA RESEARCH (2020)
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
Maria Julia Lamberti et al.
PHARMACEUTICS (2020)
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis
James C. Lee et al.
SCIENCE IMMUNOLOGY (2020)
CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer
Yi Li et al.
CANCER LETTERS (2020)
Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model
Soheila Golchin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
Qiuhua Luo et al.
CANCER LETTERS (2019)
Immunogenic cell death in cancer therapy: Present and emerging inducers
Jingyi Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Nivolumab for previously treated squamous oesophageal carcinoma
Elizabeth C. Smyth et al.
LANCET ONCOLOGY (2019)
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
So-Jin Park et al.
ORAL ONCOLOGY (2019)
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
Carlo Genova et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Pembrolizumab: living up to expectations
Stephen M. Ansell
BLOOD (2019)
Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma
Junseong Park et al.
ONCOIMMUNOLOGY (2019)
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu et al.
CANCER LETTERS (2018)
Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer
David Krantz et al.
EUROPEAN UROLOGY (2018)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Vishwanath Sathyanarayanan et al.
MOLECULAR ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Involvement of Ras GTPase-activating protein SH3 domain-binding protein 1 in the epithelial-to-mesenchymal transition-induced metastasis of breast cancer cells via the Smad signaling pathway
Hao Zhang et al.
ONCOTARGET (2015)
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
H. Inoue et al.
CELL DEATH AND DIFFERENTIATION (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Chemoimmunotherapy: reengineering tumor immunity
Gang Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice
Jian-hua Gong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Antonella Sistigu et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Claire Banissi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Michael R. Elliott et al.
NATURE (2009)
How regulatory T cells work
Dario A. A. Vignali et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Share Paper
